The CITED family of transcriptional modulators plays multiple roles in the development of vertebrates. These proteins are characterized by the conservation of a carboxy-terminal domain which defines this family and has a high affinity for the transcriptional co-activators CBP/p300. In humans, mutations in some CITED genes or deregulation of their expression are associated with developmental anomalies. In particular, CITED2 dysfunction has been associated with congenital heart disease.
INTRODUCTION
The CBP/p300 interacting transactivator with ED tail rich (CITED) family members are transcriptional modulators present in vertebrates, which bind with high affinity to the transcriptional co-activators and acetyltransferases CBP/p300 [1] [2] [3] [4] [5] [6] [7] [8] . During mouse embryogenesis, CITED proteins play pleiotropic roles, and are required for many developmental and morphological processes. Indeed, Cited1 is important for placental development, early nephrogenesis and growth of the embryos [9, 10] .
Cited2, which is the most studied gene of the family to date, is critical for embryo survival and growth during gestation and for the correct cardiac, adrenal, neural tube, liver, lung, eye, skeletal, thymus, hematopoietic and placenta development [1, 2, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . In humans, dysregulation of CITED2 expression and mutations were associated with congenital heart defects (CHD) [1, 11, [25] [26] [27] . In addition to cardiac pathologies, neonatal diabetes mellitus and insulin resistance in adults [28, 29] , and idiopathic premature ovarian failure affecting woman fertility were also observed [19] . Unlike
Cited1 and Cited2 which are critical for development, Cited4 is dispensable for embryonic development since Cited4-knockout mice are viable and fertile [30] . Interestingly, Cited4 expression in adult rodent hearts is associated with healthy cardiac hypertrophy during exercise training [31] .
Finally, the non-mammal Cited3 member, which has only been described in chicken (birds) and fish, is also involved in the correct development of these organisms [32] [33] [34] [35] . Compelling evidence has indicated that premature senescence of Cited2-null mouse embryonic fibroblasts [36] , embryonic stem cells (ESC) self-renewal and differentiation defects due to Cited2 depletion [37, 38] , as well as death and multiple organ dysfunctions in Cited2-null embryos [39] , may be rescued by supplementation or ectopic expression of human CITED2 protein. Like in mouse, a recent study in zebrafish has showed that Cited2 depletion from 1-cell stage triggers the increase of early embryonic death and developmental defects, including cardiovascular defects [40] . Interestingly, in this non-mammalian model, the defects caused by Cited2 depletion can also be rescued by microinjection of a recombinant human CITED2 protein. Thus, the human CITED2 protein shares interchangeable functions (and protein homology) with mouse and zebrafish endogenous Cited2 proteins, arguing that CITED2 protein function is conserved across vertebrates. A similar conservation of other CITED proteins' function remains unfounded.
Several reports have now pointed out the expression and the role of CITED proteins in stem cells (including ESC), in which they are involved in selfrenewal and cell fate decisions [38, [41] [42] [43] [44] [45] [46] . Not surprisingly, due to the plethora of cellular and embryonic functions exerted by CITED1, CITED2 and CITED4, these genes were also showed to play intricate roles in tumorigenic processes [5, 45, [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] . Therefore, CITED proteins are truly Regenerative Medicine Frontiers
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Cited Gene Regulatory Circuits
CITED proteins do not bind directly to DNA and act as co-activators or inhibitors of a variety of transcription factors that require a cooperation with CBP/p300 for their optimal transcriptional activity ( Figure 1 and Table 1 ). The C-terminal domain of CITED is a transactivation domain unique to this protein family, which exhibits a high binding affinity to the cysteine-histidine-rich domain-1 (CH1 domain) of CBP/p300 [7] . Through the interaction with CBP/p300, all CITED proteins may compete out other transcription factors from the CH1 domain, such as the Hypoxia-Induced Factor-1α (HIF-1α), and consequently inhibit HIF/hypoxia-mediated responses [4, 6, 7, 60, 61] . In addition to HIF-1α, CITED2 also negatively regulates the activity of other factors interacting with the CH1 domain, such as RXRα, NF-κB, STAT2, p53 and ETS-1 [7, [62] [63] [64] [65] [66] [67] . CITED1 has been showed to repress β-catenin upon activation of Wnt signalling, and to be a co-activator for Smad4 and estrogen-dependent nuclear receptors [6, 68, 69] . Both CITED2 and CITED4 are also co-activators of the TFAP2 transcription factors family, while LHX2/3, SMAD2/3, PPARɑ/γ, HNF-4ɑ, WT1 and ISL1 have only been showed to be co-activated by CITED2 [1] [2] [3] 8, 11, 37, [70] [71] [72] [73] [74] [75] . In addition, CITED2 interacts with the acetyltransferase GCN5 and under fasting conditions, CITED2 promotes PGC-1ɑ activation in response to glucagon by inhibiting the acetylation of PGC-1ɑ by GCN5 [73] . [3, 7, 64, 72, [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] . In addition, FoxP1, as well as other transcription factors required for the maintenance of pluripotency, stimulate the expression of Cited2 in mouse ESC [88] . Cited2 expression in the mesoderm is positively regulated by Wnt3/WNT3A [89] .
FoxO1 and FoxO3 may also upregulate Cited2 transcripts levels in cardiomyocytes during myocardial infarction [90] . Unlike Cited2, little is known about the stimuli governing Cited1 and Cited4 expression. The regulation of Cited1 expression by hypoxia has been evidenced in fish but remains to be established in mammals [91, 92] . Cited1 expression is also modulated by Wnt3a in ESC and by the parathyroid hormone in osteoblastic cells [93, 94] . During mouse embryonic development, Cited1
and Hand1 have overlapping expression patterns in trophoblastic tissues and heart ventricles [9, 95, 96] . Cited1 expression may also be strongly activated in mouse embryonic hearts by Neuregulin (Nrg) 1 through the ERK1/2-MAP kinase pathway, and by the cardiogenic factors Tbx20 and
Hand1, but the exact contribution of Cited1 to heart development remains unclear [96] [97] [98] . In mouse and human adipocyte progenitors, Cited4 expression is induced by the antidiabetic drug rosiglitazone [99] .
Interestingly, Cited4 expression is induced in adult rat hearts by exercise training, suggesting that Cited4 plays a role in adult heart physiology [31, 100] .
The CITED transcripts and proteins, as well as their functions, are also regulated at the post-transcriptional and post-translational level. Indeed, TGF-β cell stimulation accelerates the post-transcriptional turnover of Cited2 transcripts [101] . At the protein level, CITED1 interaction with p300
and Smad4, and its transcriptional co-activation capacity are decreased through CITED1 phosphorylation during the cell cycle [61] . In vitro, MAP kinases phosphorylate CITED2 to potentiate its capacity to co-activate TFAP2 [39] . The relevance of this post-translational modification at the cellular and developmental level remains unclear. Finally, the stability of CITED2 protein is also tightly regulated in a proteasome-dependent degradation manner [102, 103] . Multiple signalling pathways are involved in the self-renewal and maintenance of ESC by activation of Oct4, Sox2 and Nanog expression ( Figure 2 ), which are the core pluripotency master regulators [104, 105] .
CITED Proteins in Self-Renewal of Embryonic Stem Cells and

Maintenance of Pluripotent State
These transcription factors concurrently activate the expression of genes important to maintain the pluripotency state, promote cell proliferation or repress the expression of genes involved in ESC differentiation [105] . The expression of the core pluripotency factors in ESC is stringently regulated, and either an increase or a decrease of their optimal expression levels prompts ESC to differentiate. In mouse ESC, leukemia inhibitory factor (LIF) has been showed to play an essential role in the maintenance of the pluripotent state [106] . LIF binds to cell surface receptors and concurrently activates the JAK/Stat3 pathway to stimulate the expression of Klf4, an activator of Sox2, and the PI3K/AKT pathway to promote Tbx3 expression which consequently activates Nanog expression [107] . In turn, Sox2, Nanog and other auxiliary factors control the expression of Oct4 and TGF-β/ACTIVIN/NODAL-SMAD2/3 signalling pathways are critical to maintaining pluripotency of human ESC [112, 113] . The transcriptional co-activators CBP/p300 also play significant roles both in the maintenance of pluripotency and the differentiation of ESC, and they are recruited to the regulatory regions of ESC genome in association with Oct4, Sox2 and Nanog [114] .
In a Nanog-like fashion, CITED2 overexpression in mouse ESC is sufficient to sustain self-renewal and proliferation in the absence of LIF [38, 115] . Conversely, Cited2 acute depletion not only impairs proliferation, but also triggers cell death by apoptosis and spontaneous differentiation of ESC [38] . Unlike Cited2, both Cited1 and Cited4 are poorly expressed in undifferentiated ESC and might not play a major role in the maintenance of the pluripotency [43, 46] . Moreover, Cited1 overexpression in mouse ESC triggers their transition to a trophoblast-like state by activation of a trophoblast transcriptional program [43] . In undifferentiated mouse ESC, Cited2 directly controls the expression of Nanog, Tbx3 and Klf4 transcripts and the promoter activity of these genes (Figures 1 and 2, and Table 1) , and in turn, Nanog activates Cited2 promoter activity [38] . Surprisingly, a minute population of Cited2-null ESC resisting to cell death and spontaneous differentiation, and presenting characteristics of undifferentiation has been reported [38, 76] . However, Cited2-null cells fail to differentiate into cardiac, hematopoietic and neural cell lineages due to a delay in silencing Oct4 expression [76] . An inverse correlation between Oct4 and Cited2 expression levels in mouse ESC has also been reported [116] . These observations suggest that Cited2 is a negative regulator of Oct4 expression in undifferentiated ESC. Additionally, in mouse and human ESC, transcriptional regulators of pluripotency such as Oct4, Sox2, Nanog, FoxP1 and Zfp206 bind the regulatory elements that control the transcription of Cited2 [88, 117, 118] . Like the core pluripotency transcription factors expression, it appears that Cited2 expression is tightly regulated in ESC by forward and feedback regulatory loops ( Figure 2 ).
In 2007, mouse Epiblastic Stem Cells (EpiSC) were described for the first time and shown to be the mouse cells equivalent to pluripotent human ESC [119, 120] . Human ESC and EpiSC are cells concomitantly expressing the core pluripotency factors and transcripts promoting differentiation, unlike mouse ESC (now termed "naïve" or "ground state" ESC) which do not express high levels of genes involved in differentiation. In a sense, EpiSC and human ESC are one step ahead of "naïve" mouse ESC to engage differentiation and are also termed "primed" ESC. Interestingly, hypoxic treatment of mouse "naïve" ESC, or HIF-1ɑ stabilization in these cells, decrease their proliferation rate and drives them to transition from a "naïve" to a "primed" pluripotent state [121] [122] [123] In early mouse development, Cited1 protein is expressed from 2-cell to blastocyst stages and localizes primarily in the cytoplasm [43] . In blastocysts, Cited1 is mostly detected in the extraembryonic trophectoderm, and its expression in blastocyst structures is inversely correlated to Oct4 expression and activated by BMP4 [43] . These observations are in agreement with the major role played by Cited1 in placental development [9] . In humans and mice, CITED2 expression is gradually increased from one-cell to blastocyst stages with a peak at the blastocyst stage, which matches the expression of core pluripotency factors such as NANOG and SOX2 [126, 127] . Together these observations indicate that Cited2 is the only Cited-family member substantially expressed in undifferentiated ESC, and required for self-renewal in vitro and perhaps in vivo. Since the function of CITED2 is highly conserved between mice and humans, it is likely that this protein also plays a critical role in human ESC. Therefore, it would be of interest to clarify the role of CITED2, and other CITED family members in human ESC. Regen Med Front. 2019;1:e190005. https://doi.org/10.20900/rmf20190005 [129] . Perhaps reminiscent of its role in ESC pluripotency and survival [38, 115] , CITED2 expression may be critical to originate iPSC. Indeed, Cited2 depletion in immortalized mouse embryonic fibroblasts (MEF) reduced drastically their ability to initiate the reprogramming process [38] .
CITED2 and Induced Pluripotent Stem Cells Reprogramming
Conversely, CITED2 co-expression with Oct4, Sox2, Klf4 and c-Myc factors increased the efficiency of iPSC generation and accelerated the emergence of iPSC-colonies expressing Nanog [38, 130] . Interestingly, the sole overexpression of CITED2 in MEF exposed to LIF is able to unlock the expression of core pluripotency transcription factors such as Nanog, Rex1
and Sox2 [130] . Furthermore, its co-expression with Yamanaka's factors facilitated the reprogramming process and reduced the variability of some core pluripotency-related genes expression in iPSC clones, particularly if derived from pre-senescent MEF which are usually refractory to reprogramming [38, 130] . The expression of constitutively active SMAD2/3 along with Yamanaka's factors accelerated and increased the number of emerging iPSC colonies [131] . Since CITED2 is a SMAD2/3 co-activator, it would be of interest to test whether the co-expression of CITED2, SMAD2/3
and Yamanaka's factors further improves the reprogramming process [132] . In fact, SMAD2/3 were proposed to be general potentiators of direct somatic cells conversion not only for iPSC, but also to transdifferentiate a given source cell into non-pluripotent cell types with distinct functions, such as mouse B cells into macrophages, myoblasts into adipocytes, and human fibroblasts into neurons [131] . Interestingly, the direct conversion of human dermal fibroblasts into cardiac progenitors by forced expression of MESP1 and ETS2 stimulates the expression of CITED2 in intermediate cells, suggesting that CITED2 expression may participate in the conversion of fibroblasts into cardiac progenitors [133] . Like SMAD2/3, CITED2 may also act as a general potentiator of direct somatic cells conversion into cells with distinct functions. Together these observations suggest that Cited2 function is substantially associated with undifferentiated pluripotent cells, and that it is of crucial importance for the establishment and maintenance of the pluripotent state in vitro.
Role of CITED in Cardiogenesis
Recent in vitro studies using mouse ESC to unravel the role of CITED [37, 40] .
In vivo, although an extensive overlap of expression exists between
Cited1, Cited2 and Cited4 in cardiac structures during mouse development [21, 37, 95, 134, 135] , only embryos with Cited2-knockout in epiblast cells drastically fail to develop normally and die in utero with a myriad of cardiac and non-cardiac abnormalities [1, 9, 11, [13] [14] [15] [20] [21] [22] [23] [24] 30, [136] [137] [138] [139] [140] [141] .
Since Cited2 is important for the correct development and vascularization of the placenta, and that normal placental function is required for correct heart development, part of the cardiovascular defects observed in Cited2null embryos may also be a consequence of placental defects [9, 22] . A cardiomyocyte-specific Cited2-knockout revealed that Cited2 is also important for the thickening and vascularization of the myocardium during gestation [13] . On the other hand, Cited1-null mice die immediately after birth due to defects in trophoblast-derived extraembryonic tissues, while Cited4-null mice are viable and fertile, but neither Cited1-nor Cited4null mice were reported for any apparent heart defect [9, 30] . Cited1 expression may be stimulated by Nrg1 and the pro-cardiogenic transcription factors Tbx20 and Hand1 [96] [97] [98] . Importantly, mouse hearts maintain a regenerative potential up to a week after birth. Interestingly, the denervation of the heart impairs cardiac regeneration of neonatal mouse after injury, but the regeneration of denerved hearts can be rescued by administration of Nrg1 and nerve growth factor [142] . It would be of interest, to determine whether Cited1 plays any part in the heart regenerative potential of mouse neonatal pups.
At the molecular level, Cited2 amongst all Cited genes, seems to have a unique function which is to restrain HIF-1ɑ hyperactivity during mouse embryogenesis in hypoxic cardiac structures of the developing heart, such as the interventricular septum, outflow tract and atrioventricular canal regions [23, 143] . Cited2 also cooperates with Tfap2 and CBP/p300 to positively regulate Nodal, Lefty1/2, Pitx2c and Vegfa (vascular endothelial growth factor a) expression in embryos (Figures 1 and 2, [13] , corroborating the idea that Cited2 function may not be as critical after (cardiac) mesoderm specification both in vivo and in vitro.
Conversely, Cited2 itself may be important for mesoderm specification, since the depletion of Cited2 in ESC at the onset of differentiation decreases
Brachyury and Mesp1 expression which are pan-mesoderm and cardiac mesoderm markers, respectively [37] . Concordantly, high expression levels of Cited2 have been detected in early mesoderm Mesp1-positive cardiac precursors [144] . Interestingly, mesoderm progenitors originated from human ESC and iPSC also express CITED2 [145] . These in vivo and in vitro observations suggest that cardiogenic defects due to Cited2-loss of function are essentially a consequence of early mesoderm specification defects, and that CITED2 may be critical for mesoderm progenitors specification. The molecular mechanisms by which Cited2 contributes to early mesoderm specification, and its function in mesoderm progenitors are still unknown.
In addition to its role in early mesoderm specification, Cited2 may have other functions at later stages of cardiogenesis, since its expression is enriched in cardiac progenitor cells in vivo and in vitro [37, 144, 146] .
Moreover, CITED2 is a co-activator of the transcription factor ISL1, which is crucial to originate cardiac progenitors of the secondary heart field (SHF) [37] . Accordingly, it was demonstrated that the combined overexpression of ISL1 and CITED2 in ESC with a low propensity to differentiate into cardiomyocytes increases their cardiogenic potential [37] . Unlike Cited2 which is expressed in ESC and throughout differentiation although at variable levels [37] , Cited4 expression has only been detected in ESC-derived cells after the establishment of Brachyury transient expression [46] . Like Cited2, Cited4 is expressed at high levels in cardiac progenitor cells derived from ESC, its expression is transiently increased from approximately D6.5 to D8.5 during differentiation and the overexpression of either Cited2 or Cited4 in ESC stimulates cardiac differentiation [37, 46] . Thus, the roles of Cited2 and Cited4 at late cardiogenic steps may be redundant, since the knockout of Cited2 both in vivo and in vitro only drastically affects cardiogenesis when performed before mesoderm specification, at the time when Cited2 is uniquely expressed [13, 37] . It would be of interest to determine the precise function of Cited2 and Cited4 in mesoderm and cardiac progenitors. Altogether, these observations suggest that Cited2 plays a privileged role in cardiac development, a role which is not fully interchangeable with other Cited genes.
CITED, Congenital Heart Disease and Adult Heart Function
Non-synonymous and synonymous variants in CITED2 sequence or reduced expression of CITED2 have been associated with CHD worldwide [25, 26, 39, [147] [148] [149] [150] . Ventricular (VSD) and atrial (ASD) septal defects, transposition of the great arteries (TGA) and the tetralogy of Fallot (TOF) are the most frequent heart anomalies associated with CITED2 variants Regenerative Medicine Frontiers
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Regen Med Front. 2019;1:e190005. https://doi.org/10.20900/rmf20190005 ( Figure 3 ). Most of CITED2 variants identified in patients with CHD, only marginally affect its capacity to repress the transcriptional activity of HIF-1ɑ and/or to co-activate TFAP2 ex vivo [25, 26, 39, [147] [148] [149] [150] . However, CITED2 mutations in patients may result in severe impairment of VEGF and PITX2C gene expression, which are necessary for normal development of the vasculature and left-right patterning, respectively [26] .
Alternatively, mutations of CITED2 may result in HIF-1ɑ hyperactivity which may hamper cardiac development as demonstrated in mouse animal and ESC models [23] . In any case, since CITED2 cooperates with other transcription factors important for cardiovascular development, such as ISL1 and SMAD2/3 [151, 152] , the ability of CITED2 mutant proteins to co-activate these factors should also be investigated. Apart from CITED2, only an aberrant hypomethylation of the CITED1 upstream regulatory regions has been detected in monozygotic twins with double outlet right ventricle (DORV), but the role of CITED1 in the pathology remains to be ascertained [153] . To date, no reports have established any association between CITED4 dysfunction and CHD. cardiomyocytes size due to a failure in the cytokinesis after DNA replication and nuclei duplication. Thus, cardiomyocytes in adult mammalian hearts are often binucleated and sometimes multinucleated, although some mononucleated cardiomyocytes persist. The mechanism by which mammalian cardiomyocytes lose their capacity to proliferate soon after birth is still unclear, but an increase in oxygen supply at birth (hyperoxia) has been showed to inflict DNA damage in cardiomyocytes at birth and provoke their cell cycle withdrawal [154] . Hyperoxia at birth may therefore destabilize Hif-1ɑ which is required for proliferation of cardiomyocytes which are in hypoxic conditions during gestation of mammals [155] . To which extend CITED proteins contribute to Hif-1ɑ modulation in cardiomyocytes after birth remains to be investigated.
However, in cardiomyocytes isolated from 1-day old neonatal rats, Cited2 expression is associated with the inhibition of proliferation of these cells, and its downregulation by action of miR-410 and miR-495 microRNAs results in proliferation of cardiomyocytes [77] . In these cells, Cited2 has been showed to increase p57 cell cycle inhibitor expression, and decrease
Vegfa expression [77] . Thus, Cited2 expression in neonatal cardiomyocytes may promote cell cycle arrest, while in other cell types and during development, its expression is associated with cell proliferation rather than cell cycle arrest. In contrast, Cited4 promotes rat neonatal cardiomyocytes proliferation, but its expression is negatively regulated by the p27 cyclin inhibitor and the transcriptional repressor Hmbox1 [156] .
The expression of mir-222 is sufficient to increase CITED4 expression and contribute to cardiomyocytes proliferation [156] . CITED2 transcript levels were showed to be decreased in patients suffering from ischemic cardiomyopathy compared to control individuals [157] . In these patients, a positive correlation between left ventricular function and CITED2 expression has been established. Thus, the downregulation of CITED2 expression in ischemic hearts is likely to exacerbate the chronic maladaptive activation of the HIF pathway and HIF-mediated metabolic switch, which may contribute to cardiac degeneration and progression to heart failure caused by energy deprivation [157] [158] [159] . Together, these observations suggest that CITED2 [160] . Healthy cardiac hypertrophy through Cited4 expression is controlled negatively by the transcription factor C/EBPβ and positively by miR-222 [31, 156] . Cited4 may also function to restrict the elongation size of rat cardiomyocytes to physiological parameters and avoid an excessive and dysfunctional hypertrophy of these cells [100, 160] . In the context of ischemia-reperfusion injury in mouse adult hearts, Cited4 overexpression does not protect against the initial insult (infarct size is similar to control animals), but facilitates the functional cardiac recovery and increases animal survival, by reducing adverse ventricular remodelling and fibrosis [160] . Thus, in animal models, CITED2 has been shown to be a co-activator for ISL1, and together ISL1 and CITED2 cooperate to activate the promoter of cardiogenic genes, such as Mef2c, and stimulate the differentiation of ESC to cardiac lineages. It would be of interest to further explore whether a disruption of the ISL1-CITED2 cooperation may be involved in CHD. In adult hearts, the role of Cited2 for cardiac homeostasis and protection against injuries is not well established, while Cited4 has been described as a major factor for healthy heart hypertrophy.
In recent reports, Cited2 has been associated with the stemness of embryonic and adult stem cells. In ESC, Cited2 is an important auxiliary factor stimulating the expression of the core pluripotency transcription Cited members, would provide invaluable cues to therapeutically address the dysfunction of these proteins in diseases. Reminiscent of its role in ESC, Cited2 is essential for the generation of iPSC from mouse fibroblasts, indicating that Cited2 may have a role in the establishment of pluripotency in vitro. Using CITED2 in cell conversion processes may also improve cellular reprogramming and provide cells with better quality and more suitable for clinical therapies.
Overall, the precise role of CITED proteins in adult organism and in specific tissues or cell-types, including stem cells, remains largely unknown. In the future, a better knowledge of the molecular and specific cellular functions of the Cited genes will contribute to understand their roles in heart development, pathogenic or cardioprotective responses, and to develop novel therapeutic approaches to limit cardiac dysfunctions and/or restore normal cardiac functions.
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